Myrobalan Therapeutics’ Post

It was great to be in Boston proper last week, and no it wasn't to see my Celtics ☘️ ahead of the playoffs, although TD Garden was right around the corner. However, I still go to do something really exciting: attend our STAT Open Doors event to hear from industry experts about how GLP-1 treatments are transforming #healthcare.    After hearing from speakers who span across various verticals, it's clear that #GLP1 treatments can have a real impact on altering patient care pathways, reducing long-term costs, and improving patient outcomes on a macro scale. Our team (CC: Rita Glaze-Rowe) is focused on continuously evolving hypotheses and finding insights to help our clients diagnose, understand, and plan against seismic shifts like the GLP-1 market, because this space has far-reaching impact.    Innovation is in Real Chemistry's DNA — it’s what attracted me to the organization. From the very beginning to today, we've always been thinking ahead and trying to see around corners to anticipate what's on the horizon, and GLP-1 therapies will be no exception.

Lots of great data in Corum's special mid-year report on Tech M&A. Valuations and deals by sector, who are the most acquisitive buyers out there, and so much more :) ... https://lnkd.in/eXwReTix

Want to keep up-to-date with the latest news in your industry/field? 🤔 Here's a tip that some of you might already use - Google #Alerts I want to keep on top of the latest clinical and scientific data, new product developments and mergers and acquisitions in #dryeye and #contactlenses. I have a Google Alert for both and get regular emails like the one below (you can set the frequency) keeping me informed. It will also bring up new stories in the consumer media which can be useful to be forearmed to answer patient questions. Mind you it's sometimes it's a bit behind the proverbial grapevine, like today's breaking news that Trukera Medical has just been acquired by Bausch + Lomb 😮 It's also a bit weird when you or one of your businesses is featured! Do you have any other tips to staying ahead of the curve? #stayuptodate #keepahead #stayinformed #optometry #ophthalmology

Julia Isaacs, Emily Breay and the team at KNow Research don’t just talk the talk. Wrapping up Quirk's Media Event Dallas learning about the amazing work they did for Peace by PEACE and the benefits of Pro-bono work. 1. Test New Solutions- Shop for and try new tools, methodologies, deliverables in a low-risk environment. 2. Testimonials- Support business development by sharing your beneficiary's endorsement. 3. Individual Growth- Challenge team members to step out of their comfort zone and try on new research 'hats'. 4. Team Growth- Give opportunities for cross-team collaboration, with team members working together in new capacities. #facetofacemrx #mrx #quirks

Build and retain a chemistry knowledge database, eliminate duplication and ensure nothing is lost. Torx® Software allows you to view compounds which may have been made some time ago, or by chemists who have since left the organization. Capture the knowledge of today's scientists for the benefit of future drug discovery teams with Torx, the synergistic collaboration between Cresset and Elixir Software Ltd.  ➡️ https://lnkd.in/etbjyqib #DMTA #DrugDiscovery"

Is feedback important in your work? At Altoa, it definitely is. Every review helps us improve and deliver even better care. By sharing your experience, you’re contributing to the growth and enhancement of our services for future patients. Thank you for your support! 🙏 💜 Here is the link to our Google review: https://lnkd.in/eJku6yKf altoamt.com

🎉✈️ Gearing up for an exhilarating week ahead as I pack my bags for Frisco, Texas! I'm thrilled to join my esteemed peers on the Senior Leadership Team at Integer for a series of pivotal discussions. Our agenda? To align, strategize, and propel our shared vision of revolutionizing patient care on a global scale. Integer's commitment to serving leading medical device OEMs is not just a mission; it's our passion. This trip symbolizes our dedication to: 🚀 Expanding Capabilities: We're not just growing; we're evolving with state-of-the-art facilities in New Ross and Galway, amplifying our capacity to innovate and deliver. 🔍 Fostering R&D Excellence: Our relentless pursuit of breakthroughs in medical technology sets the bar high, ensuring we're at the forefront of the industry. 🌍 Targeting Growth Markets: With strategic acquisitions like InNeuroCo and Pulse Technologies, we're diving deep into critical sectors, ensuring our customers have the edge in structural heart, neurovascular, and more. 🤝 Enhancing End-to-End Solutions: Our commitment is our promise. From concept to delivery, we're redefining what it means to be a full-spectrum partner in the medical device landscape. As we meet in Frisco, our focus is clear - to strengthen our bonds, refine our strategies, and reaffirm our unwavering commitment to enhancing patient care worldwide. The journey is exhilarating, and the future is bright! #IntegerLeadership #InnovationInHealthcare #PatientCare #MedicalDeviceExcellence #GlobalImpact

Expressing appreciation for my colleagues at Premier Research is an important part of my work day. In addition to hand drawing portraits for my art appreciation series Faces Of Premier: A Look At The People Of Clinical Trials, I make time to tell five colleagues a day I appreciate them. This is something I follow because in our professional world of timelines, it could be easy to overlook those who help contribute to our success and the success of our organization. Regardless of what role we play in our company, we are just one cog in the operational machine and our efforts help keep things running smoothly and at an effective pace. At this CRO, we do what we do for the patients and our sponsors. An equally important, we're able to do what we do because of each other. Teamwork is Dreamwork! #ExpressingAppreciation #Teamwork

We are excited to share the official trailer for "Thelma," which has just been released. Prepare to be drawn into an unforgettable journey. The trailer debuted exclusively on People.com, where June Squibb's transformation into an unlikely action hero was hailed as "a must-see." #ThelmaMovie #FilmRelease #OfficialTrailer #JuneSquibb #ActionHero #MustSee #FilmIndustry #CinemaLovers #NewRelease

Here I am at the end of another chapter. As GARDP closes their North America office, I will also move on. Staying in jobs that truly focus on Infectious Diseases has not been straightforward for me through my long career. Right sizing of teams, portfolio prioritization, leadership changes, and resulting redirection of strategies, closing of offices - these have all been part of my many career transitions. Much has been written about attrition from ID/microbiology and the sluggish entry of young talent into the field. If something is to be done to make this situation better, there have to be visible ways of sustaining a talent pool in the field. The path to move to an adjacent field has very little resistance, and many colleagues I have worked with over the years have indeed done so. Companies and their investors look for outputs - success in trials or drug approvals - but what makes these things happen are strong teams. The team at Entasis was a great example of a small, highly experienced, and hardworking set of people who worked, ate, and played together to get things done. What that group did in the 3.5 years I was there was remarkable and has resulted in the approval of one drug and well on the way to the next one. That team is now scattered, and many have gone on to fields other than antiinfectives. Through the years, I have had the good fortune to land in a group that is similarly interested in working on infectious disease projects. I hope that lucky streak continues. Meanwhile, I plan to put my feet up for a bit, take on a few consulting projects to pay the bills, and cheer all the exciting innovation from the sidelines.